Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2485861-07-0
2. Kd68l3grw2
3. Refchem:1098148
4. Rocbrutinib [inn]
5. Orb1943502
6. Chembl5314539
7. Schembl21275352
8. Schembl29463602
9. Gtpl12875
10. (s)-n-[5-[[6-[2-[7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6h)-yl]-3-(hydroxymethyl)-4-pyridyl]-4-methyl-3-oxo-3,4-dihydro-2-pyrazinyl]amino]-2-[2-methyl-4-(tetrahydro-2h-pyran-4-yl)piperazin-1-yl]phenyl]acrylamide
11. Da-77517
12. Sy394072
13. Hy-156640
14. Cs-0886785
15. H40286
16. 2-propenamide, N-[5-[[6-[2-(1,3,4,6,7,8-hexahydro-7,7-dimethyl-1-oxo-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-3-(hydroxymethyl)-4-pyridinyl]-3,4-dihydro-4-methyl-3-oxo-2-pyrazinyl]amino]-2-[(2s)-2-methyl-4-(tetrahydro-2h-pyran-4-yl)-1-piperazinyl]phenyl]-
17. N-[5-[[6-[2-(1,3,4,6,7,8-hexahydro-7,7-dimethyl-1-oxo-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-3-(hydroxymethyl)-4-pyridinyl]-3,4-dihydro-4-methyl-3-oxo-2-pyrazinyl]amino]-2-[(2s)-2-methyl-4-(tetrahydro-2h-pyran-4-yl)-1-piperazinyl]phenyl]-2-propenamide
18. N-[5-[[6-[2-(4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-10-yl)-3-(hydroxymethyl)pyridin-4-yl]-4-methyl-3-oxopyrazin-2-yl]amino]-2-[(2s)-2-methyl-4-(oxan-4-yl)piperazin-1-yl]phenyl]prop-2-enamide
| Molecular Weight | 761.9 g/mol |
|---|---|
| Molecular Formula | C42H51N9O5 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 148 |
| Heavy Atom Count | 56 |
| Formal Charge | 0 |
| Complexity | 1560 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
23
PharmaCompass offers a list of Rocbrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Rocbrutinib manufacturer or Rocbrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rocbrutinib manufacturer or Rocbrutinib supplier.
A Rocbrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rocbrutinib, including repackagers and relabelers. The FDA regulates Rocbrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rocbrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rocbrutinib supplier is an individual or a company that provides Rocbrutinib active pharmaceutical ingredient (API) or Rocbrutinib finished formulations upon request. The Rocbrutinib suppliers may include Rocbrutinib API manufacturers, exporters, distributors and traders.
Rocbrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rocbrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Rocbrutinib GMP manufacturer or Rocbrutinib GMP API supplier for your needs.
A Rocbrutinib CoA (Certificate of Analysis) is a formal document that attests to Rocbrutinib's compliance with Rocbrutinib specifications and serves as a tool for batch-level quality control.
Rocbrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Rocbrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rocbrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Rocbrutinib EP), Rocbrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rocbrutinib USP).
